Trial Profile
A Phase 2a, Multicenter, Open-label Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Subjects With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naïve
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Adafosbuvir (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms OMEGA-3
- Sponsors Janssen Pharmaceutical KK
- 15 Jun 2018 Status changed from active, no longer recruiting to completed.
- 27 Feb 2018 Planned End Date changed from 1 May 2018 to 22 May 2018.
- 27 Feb 2018 Planned primary completion date changed from 1 May 2018 to 16 May 2018.